On October 9th, a significant milestone in the field of Immune-Mediated Inflammatory Diseases (IMIDs) research is set to unfold—the DoCTIS Project’s online General Assembly. This assembly, involving partners from Spain, Sweden, Italy, Germany, the UK, and the USA, marks a
Barcelona, Spain, witnessed a pivotal meeting of partners on September 26th, where they gathered to discuss the trials and analysis strategy. With candidates for the clinical trial already in the pipeline, the partners’ collaborative efforts aim to advance research and
The DOCTIS project has recently published several scientific publications that shed light on crucial advancements in single-cell genomics and potential therapeutic strategies for preventing severe COVID-19. One of the publications, titled “Sampling Time-Dependent Artifacts in Single-Cell Genomic Studies,” highlights the
“From the knowledge generated by the DOCTIS project we hope to make a leap in the way IMID patients are treated, and improve the long-term quality of life of thousands of patients”, DOCTIS coordinator To promote the activities of the
Milestones in combinatorial therapies The Work Package 6 of the DocTIS Project focuses its efforts in evaluating the combinatorial therapies in animal models of the different IMID’s and compare them to the approved monotherapies. To this purpose, the laboratory of
DOCTIS has organised a symposium event focused on “Combination therapies in common diseases: clinical and translational challenges”. This event will be held the 7th of October 2021, free of charge, online and will start at 5 p.m CET.
There is an urgent need to discover effective drug combinations that improve the limited efficacy of monotherapies in many common diseases. The present symposium will be a one-day online event where experts of both clinical and translational areas will share their experiences
CD80/86 axis blocking agent abatacept, selected among 130 immunomodulators to be tested in ACTIV-1 IM, a large randomized clinical trial on hospitalized COVID-19 patients. The candidate drug will be tested against anti-TNF therapy, CCR2/5 inhibitor and placebo in relation to
While vaccines are being developed to stop the COVID-19 pandemic, there is a major effort to prevent the high mortality associated with COVID-19 hyperinflammation. Researchers from the Vall Hebron Hospital Research Institute and IMIDomics have contributed to this endeavour by
The 20th January the eight European partners and one USA partner that constitute the DoCTIS Consortium held the kick-off meeting at the Vall Hebron University Hospital (VHIR).